M Schley1, S Topfner, K Wiech, H E Schaller, C J Konrad, M Schmelz, N Birbaumer. 1. Department of Anaesthesiology and Intensive Care Medicine, Experimental Pain Research/Pain Centre, University of Heidelberg, Faculty of Clinical Medicine, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. marcus.schley@anaes.ma.uni-heidelberg.de
Abstract
BACKGROUND:Hyperexcitability of N-methyl-d-aspartate acid (NMDA) receptors may play an important role in the development of phantom limb pain (PLP). AIM OF THE STUDY: To investigate whether early treatment with the NMDA antagonist memantine attenuates phantom pain memory formation in traumatic amputees. METHODS: In a randomized, double-blind, controlled trial 19 patients with acute traumatic amputation of the upper extremity were investigated. All patients received postoperative analgesia by continuous brachial plexus anesthesia (ropivacaine 0.375% 5 ml/h) for at least 7 days. In addition, the patients received either memantine (20-30 mg daily, n=10) or placebo (n=9) for 4 weeks. RESULTS:Memantine treatment reduced the number of requested ropivacacine bolus injections during the first week and resulted in a significant decrease of PLP prevalence and intensity at 4 weeks and 6 months follow up, but not at 12 months follow up. CONCLUSIONS: We conclude that memantine can reduce intensity of phantom limb pain and might also prevent the development of PLP. However, despite the very early begin of treatment; no long-term effect on established PLP was evident.
RCT Entities:
BACKGROUND: Hyperexcitability of N-methyl-d-aspartate acid (NMDA) receptors may play an important role in the development of phantom limb pain (PLP). AIM OF THE STUDY: To investigate whether early treatment with the NMDA antagonist memantine attenuates phantom pain memory formation in traumatic amputees. METHODS: In a randomized, double-blind, controlled trial 19 patients with acute traumatic amputation of the upper extremity were investigated. All patients received postoperative analgesia by continuous brachial plexus anesthesia (ropivacaine 0.375% 5 ml/h) for at least 7 days. In addition, the patients received either memantine (20-30 mg daily, n=10) or placebo (n=9) for 4 weeks. RESULTS:Memantine treatment reduced the number of requested ropivacacine bolus injections during the first week and resulted in a significant decrease of PLP prevalence and intensity at 4 weeks and 6 months follow up, but not at 12 months follow up. CONCLUSIONS: We conclude that memantine can reduce intensity of phantom limb pain and might also prevent the development of PLP. However, despite the very early begin of treatment; no long-term effect on established PLP was evident.
Authors: Kassondra L Collins; Hannah G Russell; Patrick J Schumacher; Katherine E Robinson-Freeman; Ellen C O'Conor; Kyla D Gibney; Olivia Yambem; Robert W Dykes; Robert S Waters; Jack W Tsao Journal: J Clin Invest Date: 2018-06-01 Impact factor: 14.808
Authors: Brian M Ilfeld; Sarah J Madison; Preetham J Suresh; Navparkash S Sandhu; Nicholas J Kormylo; Nisha Malhotra; Vanessa J Loland; Mark S Wallace; James A Proudfoot; Anya C Morgan; Cindy H Wen; Anne M Wallace Journal: Reg Anesth Pain Med Date: 2014 Mar-Apr Impact factor: 6.288
Authors: Varun Puvanesarajah; Jason A Liauw; Sheng-fu Lo; Ioan A Lina; Timothy F Witham; Allan Gottschalk Journal: Neurosurg Rev Date: 2015-02-14 Impact factor: 3.042
Authors: Brian M Ilfeld; Tobias Moeller-Bertram; Steven R Hanling; Kyle Tokarz; Edward R Mariano; Vanessa J Loland; Sarah J Madison; Eliza J Ferguson; Anya C Morgan; Mark S Wallace Journal: Pain Med Date: 2013-03-14 Impact factor: 3.750